March 2020

Manuscript

medRxiv

Flatiron-authored

Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States

Barzi, A, Miksad, RA, Surinach, A, Corvino, FA, Wang, S, Torres, AZ, Mamlouk, K, Pulgar, S, Valderrama, A, Bekaii-Saab, T, Ahn, D

January 2020

Manuscript

Pancreas

Flatiron-authored

Assessing real-world biomarker testing rates in metastatic colon cancer

Nakhoda, S, Deng, M, Iyer, P, Handorf, E, Jain, R, Meropol, NJ, Dotan, E

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

January 2020

Abstract

ASCO GI Symposium

January 2020

Abstract

ASCO GI Symposium

Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States

Morse, M, Meyer, A-M, Lawrance, M, Pereira, M, Mhatre, SK, Gaillard, V, Dayyani, F

January 2020

Abstract

ASCO GI Symposium

January 2020

Abstract

ASCO GI Symposium

January 2020

Abstract

ASCO GI Symposium

January 2020

Abstract

ASCO GI Symposium

Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts)

Stein, S, Snider, J, McCusker, M, Miksad, RA, Alexander, BM, Castellanos, EH, Backenroth, D, Schrock, AB, Madison, R, Carson, KR, Ali, SM

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

January 2020

Abstract

ASCO GI Symposium

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

January 2020

Manuscript

Acta Oncologia

Prognostic significance of cancer patient reported outcomes in cancer

Kerrigan, KC, Patel, SB, Halland, B, Ose, D, Chalmers, AW, Haydell, T, Meropol, NJ, Akerley, WL

January 2020

Manuscript

Journal of Oncology Practice

Flatiron-authored

Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States

George, DJ, Sartor, AO, Miller, K, Saad, F, Tombal, B, Kalinovsky, J, Jiao, X, Tangirala, K, Sternberg, CN, Higano, CS

January 2020

Manuscript

Clinical Genitourinary Cancer

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

Parikh, RB, Feld, EK, Galsky, MD, Adamson, BJS, Cohen, AB, Baxi, SS, Boursi, SB, Christodouleas, JP, Vaughn, DJ, Meropol, NJ, Mamtani, R

December 2019

Manuscript

Future Oncology

Flatiron-authored

December 2019

Abstract

San Antonio Breast Cancer Symposium

Initial real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+HER2-metastatic breast cancer

Carter, GC, Sheffield, KM, Gossai, A, Huang, Y, Zhu, YE, Bowman, L, Smyth, EN, Mathur, R, Cohen, AB, Baxi, SS, Rybowski, S, Chong, AL, Seidman, AD

December 2019

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

San Antonio Breast Cancer Symposium

Visualization of the relationship between survival and sequential treatments in metastatic breast cancer

Rocque, GB, Gilbert, A, Williams, CP, Nakhmani, A, Kandhare, PG, Azuero, A, Bhatia, S, Kenzik, KM, Burkard, ME

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

San Antonio Breast Cancer Symposium

Overall survival for first-line palbociclib plus letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice

DeMichele, A, Cristofanilli, M, Brufsky, A, Liu, X, Mardekian, J, McRoy, L, Layman, RM, Rugo, HS, Finn, RS

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

San Antonio Breast Cancer Symposium

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

December 2019

Abstract

American Society of Hematology Annual Meeting

December 2019

Abstract

American Society of Hematology Annual Meeting

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

December 2019

Abstract

American Society of Hematology Annual Meeting

December 2019

Abstract

American Society of Hematology Annual Meeting

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

December 2019

Abstract

American Society of Hematology Annual Meeting

Challenges and opportunities to updating prescribing information for longstanding oncology drugs

Balogh, EP, Bindman, AB, Eckhardt, SG, Halabi, S, Harvey, RD, Jaiyesimi, I, Miksad, RA, Moses, HL, Nass, SJ, Schilsky, RL, Sun, S, Torrente, JM, Warren, KE

December 2019

Manuscript

The Oncologist

Flatiron-authored

November 2019

Abstract

EU ISPOR

A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

November 2019

Abstract

EU ISPOR

November 2019

Manuscript

Cancer Medicine

October 2019

Abstract

AMCP Nexus

October 2019

Abstract

AMCP Nexus

Medicaid expansion and racial inequities in next-generation sequencing testing in oncology

Hooley, IJ, Cohen, AB, Gross, CP, Williams, ER, Adamson, BJS

October 2019

Abstract

Applying Big Data to Address the Social Determinants of Health in Oncology

Flatiron-authored

Technology-enabled clinical trials: Transforming medical evidence generation

Marquis-Gravel, G, Roe, MT, Turakhia, MP, Boden, W, Temple, R, Sharma, A, Hirshberg, B, Slater, P, Craft, N, Stockbridge, N, McDowell, B, Waldstreicher, J, Bourla, AB, Bansilal, S, Wong, JL, Meunier, C, Kassahun, H, Coran, P, Bataille, L, Patrick-Lake, B, Hirsch, BR, Reites, J, Mehta, R, Muse, ED, Chandross, KJ, Silverstein, JC, Silcox, C, Overhage, JM, Califf, RM, Peterson, ED

October 2019

Manuscript

Circulation

Flatiron-authored

October 2019

Abstract

Asian Conference on Pharmacoepidemiology

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

October 2019

Abstract

ESMO Annual Congress

October 2019

Abstract

ESMO Annual Congress

Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers

Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)

Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored